https://biopharmaperspective.com/ 2026-10-30T12:53:33+00:00 https://biopharmaperspective.com/2026/10/30/petosemtamab-keytruda-phase-3-head-neck-cancer/ 2026-10-30T12:53:33+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/261030_image.png https://biopharmaperspective.com/2026/10/29/astellas-secures-option-on-audaxs-il-12-cancer-therapy-dax-044/ 2026-10-29T13:21:44+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/261029_image.png https://biopharmaperspective.com/2026/10/28/gsk-and-hansohs-b7-h3-adc-improves-progression-free-survival-in-phase-3-osteosarcoma-trial/ 2026-10-28T10:22:32+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261028_image.png https://biopharmaperspective.com/2026/10/26/roches-divarasib-improves-survival-in-phase-3-kras-g12c-lung-cancer-trial/ 2026-10-26T02:16:40+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261026_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261026_image.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/23/moderna-and-mercks-phase-3-cancer-vaccine-the-added-benefit/ 2026-10-23T01:59:06+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261023_chart.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261023_image.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/22/astrazenecas-ultomiris-wins-fda-accelerated-approval-for-iga-nephropathy/ 2026-10-22T03:25:05+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261022_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261022_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/21/gsks-hibsago-wins-fda-approval-for-chronic-hepatitis-b/ 2026-10-21T02:53:55+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261021_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261021_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/19/viatris-and-opus-ryzumvi-wins-fda-approval-for-adult-presbyopia/ 2026-10-19T00:08:01+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261019_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261019_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/17/roches-enspryng-wins-fda-approval-for-thyroid-eye-disease/ 2026-10-17T09:21:45+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261017_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261017_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/15/immunitybios-anktiva-wins-fda-expansion-in-bladder-cancer/ 2026-10-15T12:37:34+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261015_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261015_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/14/roche-licenses-ronas-alk7-rnai-candidate-for-obesity/ 2026-10-14T01:23:11+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261014_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/13/bms-ryz101-meets-phase-3-endpoint-in-neuroendocrine-tumors/ 2026-10-13T05:37:47+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261013_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/05/eli-lillys-jaypirca-wins-fda-approval-for-first-line-cll-sll/ 2026-10-12T05:02:15+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261006_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261006_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/12/tevas-weltruza-wins-fda-approval-for-monthly-schizophrenia-treatment/ 2026-10-12T03:03:57+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261012_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261012_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/26/abbvies-juvmo-wins-fda-approval-for-parkinsons-disease/ 2026-10-10T11:19:12+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260926_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260926_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/25/mercks-remigromig-meets-phase-2b-3-endpoint-in-diabetic-macular-edema/ 2026-10-10T11:17:28+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260925_Science_image2.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260925_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image.png https://biopharmaperspective.com/2026/09/22/jjs-caplyta-meets-phase-3-trial-goal-in-bipolar-mania/ 2026-10-10T11:15:06+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260922_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260922_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/19/eli-lillys-inluriyo-verzenio-combination-wins-fda-approval-in-esr1-mutated-breast-cancer/ 2026-10-10T11:13:05+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260919_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260919_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/18/ultragenyxs-fayuvi-wins-fda-approval-as-the-first-treatment-for-sanfilippo-syndrome-type-a/ 2026-10-10T11:11:53+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260918_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260918_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/17/skyhawks-sky-0515-posts-1-59-point-cuhdrs-advantage-at-15-months/ 2026-10-10T11:08:43+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260917_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260917_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/15/biontechs-gotistobart-posts-18-5-month-median-survival-in-squamous-nsclc/ 2026-10-10T11:06:43+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260915_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260915_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/14/gsk-plans-first-line-jideytro-filing-after-94-response-rate/ 2026-10-10T11:04:13+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260914_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260914_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/13/abbvies-qulipta-meets-phase-3-goal-in-menstrual-migraine/ 2026-10-10T11:02:20+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260913_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260913_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/12/scholar-rocks-isembyld-wins-fda-approval-for-spinal-muscular-atrophy/ 2026-10-10T11:00:14+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260912_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260912_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/09/novartis-del-desiran-fails-phase-3-deepening-a-week-of-pipeline-setbacks/ 2026-10-10T10:57:04+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260909_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260909_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/07/abbvies-etentamig-cuts-progression-or-death-risk-by-60-in-phase-3-multiple-myeloma-trial/ 2026-10-10T10:54:43+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260907_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260907_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/06/gsk-licenses-hutchmeds-hmpl-a830-in-a-deal-worth-up-to-1-295-billion/ 2026-10-10T09:21:15+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260906_Science_image2.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260906_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260906_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/04/fda-approves-ionis-zanvastro-as-the-first-treatment-for-alexander-disease/ 2026-10-10T09:13:10+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260904_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260904_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/02/novartis-remibrutinib-delivers-two-phase-3-wins-in-relapsing-multiple-sclerosis/ 2026-10-10T09:11:28+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260902_Science_image2.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/01/eli-lilly-to-acquire-merida-biosciences-for-up-to-2-875-billion/ 2026-10-10T09:09:14+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260901_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260901_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/29/eli-lilly-wins-fda-approval-for-mounjaro-to-reduce-cardiovascular-risk/ 2026-10-10T09:07:43+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260829_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260829_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/25/genentech-bets-2-3-billion-on-hanmis-muscle-preserving-obesity-drug/ 2026-10-10T09:04:40+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260825_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260825_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/24/leo-pharma-bets-up-to-435-million-on-oral-therapy-for-rare-sunlight-induced-pain/ 2026-10-10T09:00:41+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260824_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260824_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/23/eli-lilly-moves-into-trans-amplifying-rna-vaccines-with-amplitude-deal/ 2026-10-10T08:58:22+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260823_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260823_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/22/johnson-johnson-wins-eu-approval-for-tecvayli-plus-darzalex-in-multiple-myeloma/ 2026-10-10T08:56:22+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260822_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260822_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/20/modernas-personalized-mrna-cancer-therapy-delivers-first-phase-3-win/ 2026-10-10T08:50:20+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260820_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260820_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/19/amylyx-turns-glp-1-biology-in-the-opposite-direction/ 2026-10-10T08:37:17+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260819_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260819_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/10/bayers-hyrnuo-wins-first-line-fda-approval-in-her2-mutant-lung-cancer/ 2026-10-10T07:43:16+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260910_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260910_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/08/novo-nordisk-halts-two-more-phase-3-ziltivekimab-trials-after-zeus-setback/ 2026-10-10T07:41:09+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260908_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260908_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/03/tevas-tev-408-meets-phase-2a-primary-endpoint-in-celiac-disease-by-reducing-gluten-induced-intestinal-damage/ 2026-10-10T07:38:27+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260903_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260903_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/31/priovant-wins-fda-approval-for-lisraya-in-dermatomyositis/ 2026-10-10T07:35:25+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260831_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260831_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/30/takeda-wins-fda-approval-for-first-in-class-mimrylo-in-polycythemia-vera/ 2026-10-10T07:32:54+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260830_Science_image2.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260830_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/28/roche-and-eli-lilly-win-fda-clearance-for-alzheimers-blood-test/ 2026-10-10T07:29:15+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260828_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260828_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/27/revolution-medicines-wins-fda-approval-for-rasonque-in-metastatic-pancreatic-cancer/ 2026-10-10T07:26:29+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260827_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260827_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/26/jazz-wins-first-line-fda-approval-for-ziihera-in-her2-positive-gastroesophageal-cancer/ 2026-10-10T07:19:15+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260826_Science_image-7.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260826_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/05/novartis-pelacarsen-fails-phase-3-lpahorizon-despite-lowering-lpa/ 2026-10-10T03:50:14+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260905_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260905_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/21/regeneron-wins-fda-approval-for-pasatru-in-ultra-rare-bone-disease/ 2026-10-10T03:45:49+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260821_Science_image.png https://biopharmaperspective.com/wp-content/uploads/2026/08/20260821_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/10/viatris-to-acquire-pacira-for-1-65b-in-non-opioid-pain-push/ 2026-10-10T03:34:23+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261010_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261010_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/09/bristol-myers-squibbs-zenbexus-cuts-progression-or-death-risk-by-51-in-phase-3-trial/ 2026-10-09T06:35:14+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261009_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261009_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/08/cerevance-solengepras-meets-phase-3-endpoint-in-parkinsons-disease/ 2026-10-08T03:42:58+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261008_Science_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261008_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/06/vaxcytes-vax-31-meets-phase-3-endpoints-versus-prevnar-20-and-capvaxive/ 2026-10-06T05:33:48+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261006_Science_image1-1-1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261006_image1-1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/02/novartis-licenses-abogens-abo2203-in-7-8b-mrna-deal/ 2026-10-02T14:03:05+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261002_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261002_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/10/01/eli-lilly-reports-eloratzp-phase-2b-and-retatrutide-phase-3-results/ 2026-10-01T12:45:49+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/10/20261001_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/10/20261001_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/30/astrazeneca-invests-2b-in-summit-to-combine-ivonescimab-with-its-adc-portfolio/ 2026-09-30T12:20:25+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260930_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260930_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/29/kodiak-phase-3-zenkuda-shows-24-week-durability-in-wet-amd/ 2026-09-29T11:31:21+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260929_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260929_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/24/grails-galleri-wins-fda-panel-backing-for-multi-cancer-blood-test/ 2026-09-24T13:43:47+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260924_Image.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260924_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/21/anthropic-opens-wet-lab-to-test-claude-in-biology-experiments/ 2026-09-21T11:39:23+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260921_Science_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/09/20260921_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/09/11/fda-pauses-opakalim-enrollment-days-after-sk-biopharmaceuticals-deal/ 2026-09-11T11:42:47+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/09/20260911_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/18/vyvgart-moves-into-autoimmune-muscle-disease-after-phase-3-win/ 2026-08-18T09:44:14+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260818_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/17/can-new-data-rescue-capricors-duchenne-cell-therapy-at-the-fda/ 2026-08-17T05:02:58+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260817_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/15/bristol-myers-squibb-bms-wins-fda-approval-for-the-first-celmod-therapy-in-multiple-myeloma/ 2026-08-14T15:10:29+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260814_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/13/why-astrazeneca-investors-rejected-a-400-billion-bms-megadeal/ 2026-08-13T11:15:52+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260813_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/12/epicrispr-raises-90-million-to-silence-disease-genes-without-cutting-dna/ 2026-08-12T10:49:11+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260812_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/11/jazz-bets-1-32-billion-on-a-precision-therapy-for-rare-epilepsy/ 2026-08-11T09:32:18+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260811_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/10/moderna-wins-fda-approval-for-the-first-mrna-flu-vaccine/ 2026-08-10T10:25:00+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260810_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/07/tarsus-bets-up-to-800-million-on-a-deuterated-vitamin-a-drug/ 2026-08-07T10:45:36+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_2_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/07/can-sionna-challenge-vertexs-cystic-fibrosis-empire/ 2026-08-07T10:40:36+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_1_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/05/jazz-to-withdraw-zepzelcas-second-line-sclc-indication-after-phase-3-failure/ 2026-08-05T12:08:43+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260805_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/04/curium-to-acquire-lantheus-in-an-8-billion-radiopharma-deal/ 2026-08-04T14:27:30+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260804_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/08/03/astrazeneca-and-bristol-myers-squibb-explore-a-400-billion-pharma-megadeal/ 2026-08-03T13:01:28+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/08/20260803.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/07/31/sanofis-pipeline-reset-signals-a-new-era-of-rd-discipline/ 2026-07-31T10:54:15+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/07/20260731_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/07/30/jj-takes-a-profit-hit-to-secure-an-in-vivo-car-t-platform/ 2026-07-30T10:11:30+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/07/20260730_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/07/29/astrazeneca-keeps-its-80-billion-goal-despite-a-major-trial-setback/ 2026-07-29T14:57:12+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/07/28/why-astrazeneca-says-drug-development-must-move-at-chinese-speed/ 2026-07-28T13:17:01+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/07/20260728_image1.png https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/2026/07/27/why-big-pharma-is-buying-biotech-again-the-patent-cliff-explained/ 2026-07-27T10:18:59+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/07/20260727_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image-1.png https://biopharmaperspective.com/2026/07/26/can-gsks-oncology-and-hiv-strategy-deliver-its-40-billion-revenue-goal-by-2031/ 2026-07-27T09:46:49+00:00 https://biopharmaperspective.com/wp-content/uploads/2026/07/20260726_image1.png https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image.png https://biopharmaperspective.com/2025/11/12/novo-nordisks-wegovy-shows-liver-health-benefits-beyond-weight-loss-in-mash-patients/ 2025-11-12T13:05:55+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/11-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/11/eli-lilly-strikes-475-m-gene-therapy-deal-with-meiragtx-for-rare-retinal-disease/ 2025-11-11T12:46:23+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/10-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/11/eli-lilly-advances-obesity-drug-pipeline-after-positive-phase-2-results/ 2025-11-10T15:02:39+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/9-ebb3b8ebacb8ec9aa9-1.png https://biopharmaperspective.com/2025/11/09/pfizer-lands-metsera-acquisition-after-novo-nordisk-bows-out-of-10-b-bidding-war/ 2025-11-08T16:36:42+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/8-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/07/lilly-novo-nordisk-reach-landmark-pricing-agreement-with-u-s-government-on-obesity-drugs/ 2025-11-07T11:25:21+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/7-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/05/bidding-war-heats-up-pfizer-vs-novo-nordisk-in-the-race-to-acquire-metsera/ 2025-11-05T14:53:37+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/6-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/04/eli-lillys-major-netherlands-plant-investment-scaling-supply-for-oral-obesity-therapy/ 2025-11-04T13:22:24+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/5-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/03/the-battle-for-metsera-pfizer-and-novo-nordisk-in-a-fierce-takeover-war/ 2025-11-03T13:20:20+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/4-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/02/americas-100-drug-import-tariff-reshaping-pharma-patents-and-patients/ 2025-11-02T06:00:08+00:00 https://biopharmaperspective.com/2025/11/01/fda-and-hhs-announce-biosimilar-reform-no-more-comparative-trials-full-interchangeability-ahead/ 2025-11-01T06:51:44+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/eb9190ebb288eca7b8-ed8facec8aa4ed8c85-ebb3b8ebacb8ec9aa9.jpg https://biopharmaperspective.com/2025/11/01/key-pharma-biotech-trends-that-defined-2025/ 2025-10-31T16:40:17+00:00 https://biopharmaperspective.com/wp-content/uploads/2025/11/ecb2abebb288eca7b8-ed8facec8aa4ed8c85-ec9db4ebafb8eca780.png